Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab
Magazine: Clinical and Translational Oncology
Date: Feb 1, 2007Radiation Oncology Medical Oncology
We report here a taxol–bevacizumab-responsive metastatic melanoma case.
Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.
CITATION Clin Transl Oncol. 2007 Feb;9(2):119-20
you maybe interested
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.